AbbVie’s $8.7 billion bet on Cerevel is risky but smart, analysts say
By Bhanvi Satija and Khushi Mandowara (Reuters) – AbbVie’s decision to buy Cerevel Therapeutics before key data on the drug developer’s experimental schizophrenia treatment may have helped it avoid a…